Sugi Predict

Sugi Predict / Compounds / SCHEMBL585117

SCHEMBL585117

SCHEMBL585117

N#Cc1c(Cl)cccc1CBr

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ TLR8 Q9NR97 1/20 0.41
▸ MPO P05164 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PNMT P11086 2/20 0.38
▸ HSD11B1 P28845 2/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MRGPRX4 Q96LA9 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669087 1.00 KDM4E (0.43) KDM4EALDH1A1L3MBTL1TLR8MPO
SCHEMBL2809185 0.85 CYP1A2 (0.39) KDM4EALDH1A1L3MBTL1CYP1A2CYP3A4
SCHEMBL10892138 0.82 KDM4E (0.44) KDM4EALDH1A1L3MBTL1TLR8MPO
SCHEMBL16555154 0.80 S1PR1 (0.48) KDM4EALDH1A1L3MBTL1TLR8MPO
SCHEMBL14527854 0.80 KDM4E (0.43) KDM4EALDH1A1L3MBTL1TLR8MPO
SCHEMBL1396993 0.80 ALDH1A1 (0.43) KDM4EALDH1A1L3MBTL1TLR8MPO
SCHEMBL13439087 0.80 KDM4E (0.43) KDM4EALDH1A1L3MBTL1TLR8MPO
Dichlobenil SCHEMBL55606 0.78 ALDH1A1 (0.55) KDM4EALDH1A1L3MBTL1CYP1A2CYP3A4
Dichlobenil SCHEMBL1701380 0.78 ALDH1A1 (0.55) KDM4EALDH1A1L3MBTL1CYP1A2CYP3A4
SCHEMBL584957 0.78 CYP1A1 (0.39) ALDH1A1L3MBTL1TLR8CYP1A2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 — — US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 — — US disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 — — EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 — — EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 — — EP disclosed
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 — — CN disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
EP-3810602-A1 COMPOUNDS CTXT Pty Limited (AU) 2021-04-28 — — EP disclosed
US-20150126513-A1 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
EP-2731940-A1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS Novartis AG (CH) 2014-05-21 — — EP disclosed
WO-2013177349-A2 QUINAZOLINEDIONES AS TANKYRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-28 — — WO disclosed
US-20130158112-A1 COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION CASE WESTERN RESERVE UNIVERSITY 2013-06-20 — — US disclosed
WO-2013008217-A1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2013-01-17 — — WO disclosed
WO-2013008217-A1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2013-01-17 — — WO disclosed
US-20120077989-A1 CYCLIC IMIDATE LIGANDS UNIVERSITEIT GENT (BE) 2012-03-29 — — US disclosed
US-20120077989-A1 CYCLIC IMIDATE LIGANDS UNIVERSITEIT GENT (BE) 2012-03-29 — — US disclosed
EP-2416879-A1 CYCLIC IMIDATE LIGANDS Universiteit Gent (BE) 2012-02-15 — — EP disclosed
WO-2010115903-A1 CYCLIC IMIDATE LIGANDS UNIVERSITEIT GENT (BE) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153710-A1 Compounds SLC10A1, ABCB11, PCSK9 KDM4E 4009/4885ALDH1A1 981/4885L3MBTL1 4863/4885
US-20130158112-A1 COMPOSITIONS AND METHODS FOR INHIBITING BETA AMYLOID SECRETION IAPP, APP, BACE1 KDM4E 4611/4885ALDH1A1 4152/4885L3MBTL1 3421/4885
US-20150126513-A1 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS TNKS1BP1, WNT1, TNKS KDM4E 181/4885ALDH1A1 1013/4885L3MBTL1 2693/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B KDM4E 800/4885ALDH1A1 1864/4885L3MBTL1 3817/4885
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D KDM4E 1408/4885ALDH1A1 2649/4885L3MBTL1 2472/4885
US-20120077989-A1 CYCLIC IMIDATE LIGANDS IDH2, CYCS, NAPRT KDM4E 1055/4885ALDH1A1 4283/4885L3MBTL1 3850/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B KDM4E 1329/4885ALDH1A1 2629/4885L3MBTL1 2521/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 KDM4E 4009/4885ALDH1A1 982/4885L3MBTL1 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.